Docetaxel radiosensitizes castration resistant prostate cancer by downregulating CAV-1.
Kevin J TuSanjit K RoyZachery KeepersManas R GartiaHem D ShuklaNrusingh C BiswalPublished in: International journal of radiation biology (2023)
Purpose: Docetaxel (dox), a noted radiosensitizer, is one of the few chemotherapy drugs approved for castration-resistant prostate cancer (CRPC), though only a fraction of CRPCs respond to it. CAV-1, a critical regulator of radioresistance, has been known to modulate dox and radiation effects. Combining dox with radiotherapy may create a synergistic anticancer effect through CAV-1 and improve CRPC patients' response to therapy. Here, we investigate the effectiveness and molecular characteristics of dox and radiation combination therapy in vitro . Materials and Methods: We used live/dead assays to determine the IC 50 of dox for PC3, DU-145, and TRAMP-C1 cells. Colony formation assay was used to determine the radioresponse of the same cells treated with radiation with/without IC 50 dox (4, 8, 12 Gy). We performed gene expression analysis on public transcriptomic data collected from human-derived prostate cancer cell lines (C4-2, PC3, DU-145, LNCaP) treated with dox for 8, 16, and 72 hours. Cell cycle arrest and protein expression were assessed using flow cytometry and western blot, respectively. Results: Compared to radiation alone, combination therapy with dox significantly increased CRPC death in PC3 (1.48-fold, p < 0.0001), DU-145 (1.64-fold, p < 0.05), and TRAMP-C1 (1.13-fold, p < 0.05) at 4 Gy of radiation. Gene expression of CRPC treated with dox revealed downregulated genes related to cell cycle regulation and upregulated genes related to immune activation and oxidative stress. Confirming the results, G2/M cell cycle arrest was significantly increased after treatment with dox and radiation. CAV-1 protein expression was decreased after dox treatment in a dose-dependent manner; furthermore, CAV-1 copy number was strongly associated with poor response to therapy in CRPC patients. Conclusions: Our results suggest that dox sensitizes CRPC cells to radiation by downregulating CAV-1. Dox + radiation combination therapy may be effective at treating CRPC, especially subtypes associated with high CAV-1 expression, and should be studied further.
Keyphrases
- cell cycle arrest
- combination therapy
- cell death
- induced apoptosis
- prostate cancer
- pi k akt
- copy number
- gene expression
- cell cycle
- oxidative stress
- end stage renal disease
- radiation induced
- newly diagnosed
- healthcare
- signaling pathway
- chronic kidney disease
- flow cytometry
- endothelial cells
- high throughput
- squamous cell carcinoma
- systematic review
- cell proliferation
- locally advanced
- poor prognosis
- mental health
- early stage
- stem cells
- rna seq
- long non coding rna
- radiation therapy
- mesenchymal stem cells
- prognostic factors
- single cell
- electronic health record
- genome wide identification
- machine learning
- ischemia reperfusion injury
- diabetic rats
- dna repair
- data analysis
- adverse drug